MedPath

Arterial infusion chemotherapy concurrent with radiation therapy followed by systemic gemcitabine and cisplatin therapy for unresectable biliary tract cancer patients; A phase2 study

Phase 2
Conditions
Biliary tract cancer
Registration Number
JPRN-UMIN000023906
Lead Sponsor
Asahikwa Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Resectable biliary tract cancer

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate, disease control rate, adverse events rate
Secondary Outcome Measures
NameTimeMethod
Median survival, protocol treatment completion rate, CA19-9 response rate, progression-free survival, distant metastasis-free survival, 1-year survival rate, 2-year survival rate
© Copyright 2025. All Rights Reserved by MedPath